- Adragos Pharma invests €13 million in a new ampoule filling line, increasing production capacity by 30%.
- The upgraded facility in France can now manufacture over 160 million ampoules annually.
Adragos Pharma, a contract development and manufacturing organisation (CDMO), has completed a €13 million ($13.8 million) investment at its Livron-sur-Drôme site in France. The enhancement includes a new ampoule filling line and a state-of-the-art cleanroom, increasing the facility’s output by 30% and allowing it to produce over 160 million ampoules annually.
The newly installed filling line, the fourth at the facility, supports flexible fill volumes ranging from 1ml to 20ml. This flexibility allows Adragos to meet a wide range of formulation needs for sterile injectables, catering to diverse customer requirements. The line is compliant with EU GMP Annex 1 regulations for aseptic fill and finish, ensuring high quality and regulatory standards.
“The new line not only addresses regulatory and capacity demands but also supports our commitment to advancing patient care by meeting the evolving needs of our clients,” said Marco Gorgas, Chief Operating Officer at Adragos Pharma.
Gaël Le Saux, Site Head of Livron, highlighted the team’s outstanding execution: “Despite the complexities, the team successfully integrated the new production line without disrupting ongoing operations.”
Overview of outsourcing trends 
